Intelligence Report · ~12 min read
TARO Pharmaceuticals Intelligence Report
Generated from 1 signals · 3 evidence sources
Type
Company Intelligence ReportGenerated
Jun 20, 2026
Confidence
Moderate Confidence · 71%
Evidence
6 items
Sources
10
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
TARO Pharmaceuticals maintains an active intelligence profile across Neurology, Anticonvulsant. 1 signals are linked with 0 investigate-priority items requiring leadership attention. Competitive pressure is low with low portfolio impact. Evidence coverage stands at 71% across 3 tracked sources. Highest-priority development: FDA TA — ANDA220639. Regulatory precedent. Why this matters: provides agency context on safety guidance that may shape timing or evidence expectations for TARO Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Key Developments
Material intelligence events ranked by strategic relevance.
- regulatory
FDA TA — ANDA220639
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — VYEPTI (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
FDA AP — NGENLA (SUPPL)
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Clinical trials for medicines: modifying a clinical trial approval
Regulatory precedent may inform portfolio positioning
View detail - regulatory
Oncology (Cancer)/Hematologic Malignancies Approval Notifications
Regulatory precedent may inform portfolio positioning
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Opportunity score 16 with buyer quality 6 (Emerging). Competitive pressure: Low. Portfolio impact: Low.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
FDA TA — ANDA220639
Moderate Confidence · 66%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — VYEPTI (SUPPL)
Moderate Confidence · 66%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — NGENLA (SUPPL)
Moderate Confidence · 66%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceClinical trials for medicines: modifying a clinical trial approval
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: MHRA, MHRA, Regunera
View evidenceOncology (Cancer)/Hematologic Malignancies Approval Notifications
Moderate Confidence · 84%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- TARO's ANDA219052 for PERAMPANEL Receives Approval Status
Neurology · Anticonvulsant